经会阴与经直肠磁共振成像靶向前列腺穿刺活检:前瞻性研究的系统评价与荟萃分析
该系统评价与荟萃分析纳入3项前瞻性随机对照试验(PREVENT、ProBE-PC和PERFECT),比较经会阴(TP)与经直肠(TR)磁共振成像(MRI)靶向前列腺穿刺活检的有效性和安全性。结果显示两种方法在临床显著前列腺癌(csPCa,ISUP≥2)和ISUP 1前列腺癌检出率、术后感染、脓毒症和尿潴留率方面均无显著差异,TP途径疼痛略高但7天后差异极小。TP-Tbx可安全省略抗生素而不增加感染风险。
要点
- TP-Tbx与TR-Tbx在csPCa(OR 0.9,95%CI 0.7-1.1)和ISUP 1前列腺癌(OR 1.1,95%CI 0.8-1.4)检出率无显著差异。
- 术后感染(OR 0.8,95%CI 0.4-1.8)、脓毒症(OR 0.6,95%CI 0.1-4.5)和尿潴留(OR 0.5,95%CI 0.1-1.6)率相似。
- TP途径疼痛略高于TR途径,但随访7天后两种方法差异极小。
核心结论
- TP-Tbx与TR-Tbx在检出前列腺癌方面结果相似,感染、尿潴留和活检相关疼痛管理效果相当。
- TP-Tbx可安全省略抗生素而不增加感染风险,不同于TR-Tbx;因感染担忧而将TR-Tbx联合预防性抗生素排除在实践之外的倾向可被缓和,但感染和脓毒症等关键结局方向有利于TP途径,尽管缺乏统计学显著性。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed/Medline、Scopus和Web of Science截至2024年5月的前瞻性随机对照试验(RCT),纳入3项RCT(PREVENT、ProBE-PC和PERFECT),比较TP-Tbx与TR-Tbx。
主要发现
- TP-Tbx与TR-Tbx的csPCa检出率无差异(OR 0.9,95%CI 0.7-1.1)。
- TP-Tbx与TR-Tbx的ISUP 1前列腺癌检出率无差异(OR 1.1,95%CI 0.8-1.4)。
- 术后感染率(OR 0.8,95%CI 0.4-1.8)、脓毒症率(OR 0.6,95%CI 0.1-4.5)和尿潴留率(OR 0.5,95%CI 0.1-1.6)在两组间相似。
- TP途径疼痛略高于TR途径,但随访7天后两种方法差异极小。
关键数值与推荐
- TR技术通常联合抗生素预防以降低感染风险或于直肠拭子后实施。
- TP-Tbx可安全省略抗生素而不增加感染风险。
临床怎么用
- TP-Tbx可安全省略抗生素而不增加感染风险,不同于TR-Tbx。
- 因感染担忧而将TR-Tbx联合预防性抗生素排除在实践之外的倾向可被缓和。
局限性
- 每例患者活检针数、患者选择、5α还原酶抑制剂使用、针头尺寸、TP技术和疼痛评分(仅一项RCT报告)存在变异,以及RCT的多中心性质,限制了研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The benefits of the detection of clinically significant prostate cancer (csPCa) and safety of magnetic resonance imaging (MRI)-targeted transperineal (TP) prostate biopsy (TP-Tbx) versus transrectal (TR) approaches are still a matter of debate. This review aims to compare the efficacy and safety of TP-Tbx and MRI-targeted TR biopsy (TR-Tbx). METHODS: A systematic literature search was performed in PubMed/Medline, Scopus, and Web of Science to identify records of prospective randomized controlled trials (RCTs) comparing TP-Tbx and TR-Tbx published until May 2024. The primary outcomes included detection rates of csPCa (International Society of Urological Pathology [ISUP] ≥2) and rates of complications. KEY FINDINGS AND LIMITATIONS: Three RCTs (PREVENT, ProBE-PC, and PERFECT) met the inclusion criteria. The TR technique was commonly administered with antibiotic prophylaxis to mitigate infection risks or after a rectal swab. No difference was found between TP-Tbx and TR-Tbx in terms of either csPCa (odds ratio [OR] 0.9, 95% confidence interval [CI]: 0.7-1.1) or ISUP 1 prostate cancer (PCa; OR 1.1, 95% CI: 0.8-1.4) detection. Postprocedural infection (OR 0.8, 95% CI: 0.4-1.8), sepsis (OR 0.6, 95% CI: 0.1-4.5), and urinary retention rates (OR 0.5, 95% CI: 0.1-1.6) were similar. Pain during the TP approach was slightly higher than during the TR approach, but after 7 d of follow-up, the differences between the two approaches were minimal. Variations in biopsy numbers per patient, patient selection, use of 5-alpha reductase inhibitors, needle sizes, TP techniques, and pain scores (reported in only one RCT), along with the multicenter nature of RCTs, limit the study. CONCLUSIONS AND CLINICAL IMPLICATIONS: TP-Tbx and TR-Tbx show similar results in detecting PCa, with comparable rates of infections, urinary retention, and effectiveness in managing biopsy-associated pain. TP-Tbx can safely omit antibiotics without increasing infection risk, unlike TR-Tbx. The tendency to exclude from practice TR-Tbx with prophylactic antibiotics due to infection concerns could be moderated; however, the directionality of some key outcomes, as infections and sepsis, favor the TP approach despite a lack of statistical significance. PATIENT SUMMARY: There were no significant differences in the prostate biopsy approaches (transperineal [TP] vs transrectal [TR]) for prostate cancer detection and complications. However, the MRI-targeted TP prostate biopsy approach may be advantageous as it can be performed safely without antibiotics, potentially reducing antibiotic resistance.
引用
- Zattoni F, Rajwa P, Miszczyk M, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Prostate Biopsy: A Systematic Review and Meta-analysis of Prospective Studies. Eur Urol Oncol. 2024. PMID: 39095298. doi:10.1016/j.euo.2024.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。